
Total population, n=5,094
treated in buffer zones, n=1,637
eligible for randomization, n=3,457
Enrollment
Clusters (n=16)
Allocation
Intervention (n=1,110)
Clusters (n=8)
Control (n=2,347)
Clusters (n=8)
Eligible, n=1,026
Not eligible, n= 84
Pregnant (n= 27, 25 received alternative drug)
Below 1 year of age (n=26, received no drugs)
Allergic to sulphadoxine-pyrimethamine (n=3)
Received full dose of antimalarials <14d (n=23)
Unable to consent (mental illness, n=2; alcoholic, n=4)
Eligible, n=2,268
Not eligible, n= 79
Below 1 year of age (n=70, received no drugs)
Unable to consent (alcoholic, n=9)
Refused completely, n= 33
Religious reasons (n= 5)
No reason given (n=27)
Refused completely, n= 84
Religious reasons (n= 3)
No reason given (n=81)
Treated with gametocytocidal drug combination:
Received dose 1 under supervision, n=993
Received dose 1-2 under supervision, n=990
Received dose 1-3 under supervision, n=978 (35 no PQ)
Treated with placebo:
Received dose 1 under supervision, n=2,184
Received dose 2-3, n=2,184 (no supervision)
Arrived after the initial intervention (n=91):
Received dose 1 under supervision, n=91
Received dose 1-2 under supervision, n=91
Received dose 1-3 under supervision, n=91 (3 no PQ)
Arrived after the initial intervention (n=114):
Received dose 1 under supervision, n=114
Received dose 2-3 under supervision, n=114
Analysis
Passive case detection: 1,201 individuals, 7 months
Active case detection: n=149, 1043 person-months
Cross-sectional surveys, n=1303 observations
Jan-Feb n=284; Apr n=261; May n= 227; Jun n= 172; Jul n=360
Passive case detection: n=2,461, 7 months
Active case detection: n=143, 1001 person-months
Cross-sectional surveys, n=1130 observations
Jan-Feb n=212; April n 223; May n=223; June n=172; Jul n=300